Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Down 6.0% in January

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) was the target of a significant decline in short interest during the month of January. As of January 31st, there was short interest totalling 5,030,000 shares, a decline of 6.0% from the January 15th total of 5,350,000 shares. Based on an average daily trading volume, of 882,500 shares, the short-interest ratio is currently 5.7 days. Approximately 9.1% of the company's shares are short sold.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. Scotiabank upped their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a "sector outperform" rating in a research report on Monday, December 9th. StockNews.com lowered shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Friday, February 14th. Finally, Royal Bank of Canada upped their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an "outperform" rating in a research report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $56.33.

Agios Pharmaceuticals Stock Up 4.3 %

Shares of Agios Pharmaceuticals stock traded up $1.47 during trading hours on Friday, hitting $35.22. The company's stock had a trading volume of 1,018,352 shares, compared to its average volume of 758,319. Agios Pharmaceuticals has a 1-year low of $26.66 and a 1-year high of $62.58. The business has a fifty day moving average of $34.36 and a 200 day moving average of $43.08. The company has a market capitalization of $2.02 billion, a PE ratio of 3.11 and a beta of 0.88.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. On average, sell-side analysts anticipate that Agios Pharmaceuticals will post -6.85 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Tsveta Milanova sold 2,804 shares of the company's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the transaction, the insider now owns 18,906 shares of the company's stock, valued at approximately $608,395.08. This represents a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 4.93% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. State Street Corp boosted its stake in shares of Agios Pharmaceuticals by 10.2% in the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company's stock valued at $103,586,000 after purchasing an additional 216,484 shares during the period. Vestal Point Capital LP purchased a new position in shares of Agios Pharmaceuticals in the third quarter valued at $33,767,000. BNP Paribas Financial Markets boosted its stake in shares of Agios Pharmaceuticals by 15.1% in the third quarter. BNP Paribas Financial Markets now owns 11,946 shares of the biopharmaceutical company's stock valued at $531,000 after purchasing an additional 1,570 shares during the period. FMR LLC boosted its stake in shares of Agios Pharmaceuticals by 283.2% in the third quarter. FMR LLC now owns 45,393 shares of the biopharmaceutical company's stock valued at $2,017,000 after purchasing an additional 33,546 shares during the period. Finally, Intech Investment Management LLC bought a new position in Agios Pharmaceuticals during the 3rd quarter valued at $892,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.